Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

153 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Role of iron in T cell activation: TH1 clones differ from TH2 clones in their sensitivity to inhibition of DNA synthesis caused by IgG Mabs against the transferrin receptor and the iron chelator deferoxamine.
Thorson JA, Smith KM, Gomez F, Naumann PW, Kemp JD. Thorson JA, et al. Among authors: kemp jd. Cell Immunol. 1991 Apr 15;134(1):126-37. doi: 10.1016/0008-8749(91)90336-a. Cell Immunol. 1991. PMID: 1826464
The role of iron and iron binding proteins in lymphocyte physiology and pathology.
Kemp JD. Kemp JD. J Clin Immunol. 1993 Mar;13(2):81-92. doi: 10.1007/BF00919264. J Clin Immunol. 1993. PMID: 8320312 Review.
Transferrin receptor synthesis is an early event in B cell activation.
Futran J, Kemp JD, Field EH, Vora A, Ashman RF. Futran J, et al. Among authors: kemp jd. J Immunol. 1989 Aug 1;143(3):787-92. J Immunol. 1989. PMID: 2473110
Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor.
Kemp JD, Cardillo T, Stewart BC, Kehrberg E, Weiner G, Hedlund B, Naumann PW. Kemp JD, et al. Cancer Res. 1995 Sep 1;55(17):3817-24. Cancer Res. 1995. PMID: 7641199
Differing sensitivity of non-hematopoietic human tumors to synergistic anti-transferrin receptor monoclonal antibodies and deferoxamine in vitro.
Kovar J, Naumann PW, Stewart BC, Kemp JD. Kovar J, et al. Among authors: kemp jd. Pathobiology. 1995;63(2):65-70. doi: 10.1159/000163935. Pathobiology. 1995. PMID: 8554701
Identification of a murine pan-T cell antigen which is also expressed during the terminal phases of B cell differentiation.
Gulley ML, Ogata LC, Thorson JA, Dailey MO, Kemp JD. Gulley ML, et al. Among authors: kemp jd. J Immunol. 1988 Jun 1;140(11):3751-7. J Immunol. 1988. PMID: 2897394
Inhibition of lymphocyte activation with anti-transferrin receptor Mabs: a comparison of three reagents and further studies of their range of effects and mechanism of action.
Kemp JD, Thorson JA, Gomez F, Smith KM, Cowdery JS, Ballas ZK. Kemp JD, et al. Cell Immunol. 1989 Aug;122(1):218-30. doi: 10.1016/0008-8749(89)90162-7. Cell Immunol. 1989. PMID: 2526689
Synergistic inhibition of lymphoid tumor growth in vitro by combined treatment with the iron chelator deferoxamine and an immunoglobulin G monoclonal antibody against the transferrin receptor.
Kemp JD, Smith KM, Kanner LJ, Gomez F, Thorson JA, Naumann PW. Kemp JD, et al. Blood. 1990 Sep 1;76(5):991-5. Blood. 1990. PMID: 2393721
A patient with simultaneous absence of "classical" natural killer cells (CD3-, CD16+, and NKH1+) and expansion of CD3+, CD4-, CD8-, NKH1+ subset.
Ballas ZK, Turner JM, Turner DA, Goetzman EA, Kemp JD. Ballas ZK, et al. Among authors: kemp jd. J Allergy Clin Immunol. 1990 Feb;85(2):453-9. doi: 10.1016/0091-6749(90)90155-w. J Allergy Clin Immunol. 1990. PMID: 2303649
Two mechanisms of transferrin receptor induction by anti-Ig in B cells.
Vora A, Stunz LL, Kemp JD, Ashman RF. Vora A, et al. Among authors: kemp jd. J Immunol. 1990 Oct 1;145(7):2099-104. J Immunol. 1990. PMID: 2168917
153 results
Jump to page
Feedback